Shares of Hims & Hers Health Inc. have roughly doubled over the past year, and Chief Executive Andrew Dudum cashed in on the ...

Hims & Hers Health (NYSE:HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s CEO ...

Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

HIMS leverages its consumer-first telehealth model, AI-driven personalization and global expansion plans to outpace industry growth.

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Dudum sold 660,000 shares of Hims & Hers Health. The total transaction value is $33,384,120. The ...

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

We recently published 10 Big Names Bleed Double Digits. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the worst-performing ...

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...